Skip to main content
Top of the Page
Drugs

Post Marketing Surveillance/Drug Sampling

The WSMA strongly endorses physicians' participation in post-marketing surveillance, including working with the State Department of Health to seek grant or contract funds to assure the surveillance program increases. The WSMA opposes any "novel" legislation or regulatory action that would restrict the reasonable conduct of drug sampling of licensed practitioners. (Res 37, C 87; Res 5, A-90) (Reaffirmed A-17)


Return to the WSMA Policy Compendium index


Abbreviations for House of Delegates report origination:

EC – Executive Committee; BT – Board of Trustees; CPA – Council on Professional Affairs; JC – Judicial Council; CHS – Community and Health Services

Join or renew your membership today